

1 **Exercise-induced improvements in liver fat and endothelial function are not sustained**
2 **12 months following cessation of exercise supervision in non-alcoholic fatty liver disease**
3 **(NAFLD)**

4 Christopher J.A. Pugh¹, Victoria S. Sprung^{2,3}, Helen Jones⁴, Paul Richardson⁵, Fariba
5 Shojaee-Moradie⁶, A. Margot Umpleby⁶, Daniel J. Green^{4,7}, Nigel T. Cable^{4,8}, Mike I.
6 Trenell⁹, Graham J. Kemp^{2,10} & Daniel J. Cuthbertson^{2,3}

7 ¹*Cardiff School of Sport, Cardiff Metropolitan University, Cardiff, UK*

8 ²*Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University*
9 *of Liverpool, UK*

10 ³*Obesity and Endocrinology Research Group, University Hospital Aintree, Liverpool, UK,*

11 ⁴*Research Institute for Sport & Exercise Science, Liverpool John Moores University, UK*

12 ⁵*Department of Hepatology, Royal Liverpool University Hospital, UK*

13 ⁶*Diabetes and Metabolic Medicine, Faculty of Health and Medical Sciences, University of*
14 *Surrey, UK*

15 ⁷*School of Sport Science, Exercise & Health, The University of Western Australia*

16 ⁸*Department of Sports Science, Aspire Academy, Qatar*

17 ⁹*Institute of Cellular Medicine, Newcastle University, Newcastle, UK*

18 ¹⁰*Magnetic Resonance and Image Analysis Research Centre (MARIARC), University of*
19 *Liverpool, UK*

21 **Running title:** Liver fat, endothelial function and exercise in NAFLD

22 **Correspondence:**

23 Dr Daniel Cuthbertson
24 Department of Obesity and Endocrinology,
25 University Hospital Aintree,
26 Lower Lane, Liverpool L9 7AL
27 Tel: +44 (0) 151 529 5911
28 Fax: +44 (0) 151 529 5888
29 E-mail: daniel.cuthbertson@liverpool.ac.uk

31 Word Count (abstract): 218

32 Word count (excluding abstract, figures, tables and references): 1291

33 This study was funded by the European Federation for the Study of Diabetes (EFSD).

34 Clinicaltrials.gov identifier: NCT01834300

35 The authors have nothing to declare.

36 **Abstract**

37 **Aims** Supervised exercise reduces liver fat and improves endothelial function, a surrogate of
38 cardiovascular disease risk, in non-alcoholic fatty liver disease (NAFLD). We hypothesised
39 that after a 16-week supervised exercise program, patients would maintain longer-term
40 improvements in cardiorespiratory fitness, liver fat and endothelial function.

41 **Materials and Methods.** Ten NAFLD patients [5/5 males/females, age 51 ± 13 years, BMI
42 $31\pm 3\text{kg.m}^2$ (mean \pm SD)] underwent a 16-week supervised moderate-intensity exercise
43 intervention. Biochemical markers, cardiorespiratory fitness ($\text{VO}_{2\text{peak}}$), subcutaneous, visceral
44 and liver fat (measured by magnetic resonance imaging and spectroscopy respectively) and
45 brachial artery flow-mediated dilation (FMD) were assessed at baseline, after 16 weeks
46 supervised training and 12-months after ending supervision.

47 **Results** Despite no significant change in body weight, there were significant improvements in
48 $\text{VO}_{2\text{peak}}$ [$6.5\text{ml.kg}^{-1}.\text{min}^{-1}$ (95% CI 2.8, 10.1); $P=0.003$], FMD [2.9% (1.5, 4.2); $P=0.001$],
49 liver transaminases ($P<0.05$) and liver fat [-10.1% (-20.6, 0.5); $P=0.048$] immediately after
50 the 16-weeks supervised training. Nevertheless, 12-months after ending supervision, $\text{VO}_{2\text{peak}}$
51 [$0.9\text{ml.kg}^{-1}.\text{min}^{-1}$ (-3.3 5.1); $P=0.65$], FMD [-0.07% (-2.3, 2.2); $P=0.95$], liver transaminases
52 ($P>0.05$) and liver fat [1.4% (-13.0, 15.9); $P=0.83$] were not significantly different from
53 baseline.

54 **Conclusions** Twelve months following cessation of supervision, exercise-mediated
55 improvements in liver fat and other cardiometabolic variables had reversed with
56 cardiorespiratory fitness at baseline levels. Maintenance of high cardiorespiratory fitness and
57 stability of body weight are critical public health considerations for the treatment of NAFLD.

58

59

60

61 **Introduction**

62 Non-alcoholic fatty liver disease (NAFLD) increases liver-related morbidity and mortality¹,
63 yet cardiovascular disease (CVD) is the leading cause of its mortality². We need effective
64 sustainable interventions to reverse NAFLD and reduce cardiovascular risk. In the absence of
65 approved pharmacological treatment, structured exercise and/or dietary modification are
66 recommended first-line treatment in NAFLD³. The cardiometabolic benefits of supervised
67 exercise, which include reduced liver fat, enhanced peripheral insulin sensitivity and
68 microvascular and conduit-artery endothelial function^{4,5}, do not require weight loss. Parallel
69 improvements in liver fat and cardiac structure and function⁶ emphasise the role of exercise
70 as an intervention to reduce both hepatic and CVD risk.

71 We hypothesised that after a 16-week supervised exercise program, patients would maintain
72 the longer-term improvements in cardiorespiratory fitness, liver fat and endothelial function.
73 To test this we re-examined a subset of previously-reported patients^{4,5} a year after ending
74 exercise supervision.

75

76 **Methods**

77 At baseline, NAFLD was diagnosed by a hepatologist based on raised transaminases (after
78 exclusion of secondary causes) with confirmation of elevated liver fat ($\geq 5.5\%$) by magnetic
79 resonance spectroscopy (¹H MRS). All participants were physically inactive (<2 h/week low-
80 intensity physical activity) Caucasians, with no history of excessive alcohol intake (males
81 <21, females <14 units/week); normotensive, normoglycaemic non-smokers with no
82 contraindications to exercise; females were post-menopausal.

83 Patients who completed a 16-week structured and supervised exercise intervention were
84 offered the opportunity to repeat assessments 12-months later. From the original study cohort,
85 10 patients who completed the exercise intervention^{4,5} (5 males, 5 females; 51±13y; BMI

86 31±3kg.m⁻²) underwent repeat assessments 12-months later. All participants remained with
87 similar alcohol intake and as normotensive, normoglycaemic non-smokers. Liverpool Central
88 Research Ethics Committee approved the study, and all participants gave written informed
89 consent.

90 Measurements were performed fasted at baseline, after 16-weeks supervised exercise training
91 and 12-months after its end⁵. Anthropometric measurements were taken and blood samples
92 collected for plasma glucose, lipid profiles and liver enzymes.

93 Magnetic resonance scanning at 1.5T was as previously described⁵. Abdominal visceral
94 (VAT) and subcutaneous adipose tissue (SAT) were calculated from whole-body axial T1-
95 weighted fast spin echo scans. Total abdominal adipose tissue (AT) = VAT + SAT. Liver fat
96 was measured using ¹H MRS and expressed as % CH₂ lipid amplitude relative to water signal.

97 High-resolution ultrasound (Terason, t3000, Aloka, UK) was used to image the brachial
98 artery after 30min supine rest. Endothelial-dependent function was assessed as flow-mediated
99 dilation (FMD): brachial artery diameter, flow and shear stress were measured before and
100 after 5min forearm cuff inflation, and FMD is peak artery diameter following hyperaemia,
101 expressed as % increase using an allometric model. Endothelium-independent function was
102 assessed by imaging 1min before and 10min after sublingual (400 µg) glyceryl trinitrate
103 (GTN)⁷.

104 Cardiorespiratory fitness⁵ was assessed on a treadmill ergometer, initially 2.7 km.h⁻¹ at 5°
105 gradient, with step-wise increments every minute. VO_{2peak} was calculated from expired gas
106 (Oxycon Pro, Jaeger, Germany) as the highest consecutive 15s periods of oxygen uptake in
107 the last minute before exhaustion. No self-reported or objective assessment of physical
108 activity and/or exercise was made following the cessation the 16-week structured exercise
109 intervention.

110 For the exercise training intervention, an exercise physiologist provided supervision and
111 guidance. Based upon individual basal fitness, participants underwent 30min moderate
112 intensity aerobic exercise 3 times/week at 30% heart rate reserve (HRR), progressing weekly
113 based on HR responses in the initial 4-weeks. Intensity increased to 45% HRR for the
114 following 4-weeks, until week 8, where HRR remained at 45% but each session increased to
115 45min. From week 12, participants were exercising 5 times/week for 45min at 60% HRR.
116 Upon completion of the supervised exercise patients had no contact from the research team
117 for 12-months.

118 A general linear model with repeated measures was employed to evaluate differences
119 between baseline, immediate and 12-months post-training data. Analyses were performed
120 using SPSS 21.0 (SPSS, Chicago, Illinois). All data in the text, figure and table, including
121 changes, are presented as mean (95% confidence intervals), except age and BMI (presented
122 as mean and standard deviation). Intra-observer coefficients of variation for measurements of
123 liver fat and FMD were 6.0⁸ and 6.7 %⁹, respectively.

124

125 **Results**

126 Body weight did not change significantly from baseline over the training period [change = -
127 1.9kg (-1.5, 5.2); $P=0.29$], or 12-months following its completion [-0.2kg, (-3.6, 3.1);
128 $P=0.90$; Figure 1].

129 VO_{2peak} increased [6.5ml.kg⁻¹.min⁻¹ (95% CI 2.8, 10.1); $P=0.003$] and waist circumference
130 decreased [-6cm (-9, -2); $P=0.004$] following training, but had returned to baseline 12-months
131 later [0.9ml.kg⁻¹.min⁻¹ (-3.3, 5.1); $P=0.67$; Figure 1 & -1cm (-7, 5); $P=0.60$; Table 1
132 respectively].

133 Liver fat [-10.1% (-20.6, 0.5); $P=0.048$], ALT [-20u/L (-41, 1); $P=0.05$] and AST [-11u/L (-
134 21, -1); $P=0.04$] decreased following training but had returned to baseline 12-months later
135 [1.4% (-13.0, 15.9); $P=0.83$]; Figure 1; 10u/L (-21, 41); $P=0.48$ & 2u/l (-11, 16); $P=0.70$;
136 Table 1 respectively]. There were no significant changes in VAT, SAT or total AT ($P>0.20$;
137 Table 1).

138 FMD improved [2.9% (1.5, 4.2); $P=0.001$] following training, but had returned to baseline 12
139 months later [-0.07% (-2.3, 2.2); $P=0.95$; Figure 1]. There were no significant differences in
140 endothelium-independent (GTN-mediated) dilation ($P=0.74$; Table 1).

141 Patients who lost the most weight during the 16-week intervention period had the smallest
142 gain in liver fat between weeks 16 and 68 ($P=0.03$); 1kg reduction in body weight at 16-
143 weeks reduced the change in liver fat by ~4.5% in the following 52-week period.

144

145 **Conclusion**

146 Longitudinal data suggest that whilst vigorous physical activity can prevent liver fat
147 accumulation, adherence to current national and international physical activity guidelines
148 alone is not sufficient to prevent NAFLD ¹⁰. A recent study demonstrated that 8-weeks
149 aerobic exercise can reduce liver fat, irrespective of exercise volume and intensity ¹¹.
150 Following 16-weeks of supervised exercise training in the present cohort, liver fat
151 significantly decreased and FMD increased by 2.8%, extrapolated from meta-analysis data to
152 confer a CVD risk reduction of ~17% ¹². Nevertheless, this improvement had disappeared 12-
153 months after cessation of exercise supervision.

154 To the authors' knowledge, no study to date has undertaken longer-term follow-up of the
155 exercise-induced improvements in liver and vascular health following cessation of

156 supervision. This study suggests that short-term exercise interventions have only short-term
157 benefits.

158 By contrast, improvements in liver transaminases, liver fat and insulin resistance observed
159 after a 6-month hypocaloric diet with dietary counselling, were maintained for 17-36 months
160 after ending counselling, despite modest weight regain ¹³; but this study did not examine the
161 effects on CVD risk, the leading cause of mortality in NAFLD ^{2, 14}. In our study, changes in
162 liver fat and FMD were strongly associated with changes in cardiorespiratory fitness,
163 suggesting that maintenance of exercise-induced improvements in cardiometabolic
164 parameters depends upon sustained cardiorespiratory fitness. It therefore appears that
165 exercise and hypocaloric diet interventions modulate liver fat content across different time
166 courses and perhaps via distinct mechanisms. Indeed, as little as 7 consecutive days of 60min
167 treadmill walking improves liver fat and increases insulin sensitivity in obese individuals
168 with NAFLD ¹⁵. These data suggest that an increase in levels of physical activity with
169 exercise training dynamically modulates liver fat, and that to achieve prolonged
170 cardiometabolic benefits, higher levels of fitness must be maintained. Although the patients
171 were counselled on the benefits of exercise and encouraged to maintain their exercise training
172 without further guidance, physical fitness returned to pre-intervention level, suggesting that
173 long-term supervision or alternative strategies of exercise provision are required.

174 Limitations of this exploratory pilot study include a relatively small patient cohort, and a lack
175 of intermediate post-intervention assessments and measures of insulin resistance. Follow up
176 assessments were based on patient choice and thus there is the possibility of cohort bias.

177 In summary, whilst 16-weeks of supervised exercise effectively improves liver fat and
178 endothelial function in NAFLD, the cardiometabolic benefit of training is not sustained 1
179 year after ending supervision. To overcome the NAFLD epidemic we need an effective
180 mechanism to promote long-term maintenance of fitness.

181 **Acknowledgements** Thank you to all the patients for their participation in the study.

182 **Funding** We would like to thank the European Federation for the Study of Diabetes (EFSD)
183 for funding the study.

184 **Duality of interest** Nil

185 **Contribution statement** G.J.K., P.R., A.M.U., D.J.G., N.T.C., H.J., and D.J.C. conception
186 and design of research; C.J.P., V.S.S., F.S.-M., H.J., and D.J.C. performed experiments;
187 C.J.P., V.S.S., G.J.K., F.S.-M., A.M.U., D.J.G., N.T.C., H.J., and D.J.C. analyzed data; C.J.P.,
188 V.S.S., G.J.K., P.R., F.S.-M., A.M.U., D.J.G., N.T.C., H.J., and D.J.C. interpreted results of
189 experiments; C.J.P., V.S.S., P.R., H.J., and D.J.C. prepared figures; C.J.P., H.J., and D.J.C.
190 drafted manuscript; C.J.P., V.S.S., G.J.K., P.R., F.S.-M., A.M.U., D.J.G., N.T.C., H.J., and
191 D.J.C. edited and revised manuscript; C.J.P., V.S.S., G.J.K., P.R., F.S.-M., A.M.U., D.J.G.,
192 N.T.C., H.J., and D.J.C. approved final version of manuscript.

193

194

195

196

197


198

199

200

201

202



203
 204 **Figure 1** Changes in **A**) cardiorespiratory fitness (VO_{2peak}), **B**) liver fat (%), **C**) flow
 205 mediated dilatation (FMD) (%) and **D**) body weight at baseline ('Pre-ex'), following 16
 206 weeks of supervised exercise training ('Post-ex') and 12-months following cessation of
 207 exercise supervision ('1 year'). Data are presented as mean (95% CI) and as individual
 208 patients' values.

209 **Table 1 Characteristics of NAFLD patients at baseline ('Pre-Ex'), immediately**
 210 **following 16-weeks of supervised exercise training ('Post-ex') and 12 months following**
 211 **('1 year') the cessation of supervised exercise.**

212

	Pre-Ex	Post-Ex	1 year	P
Anthropometrics				
Weight (kg)	84.4(75.6, 93.1)	82.1(72.7, 91.5)	83.8(70.6, 97.0)	0.40
BMI (kg.m ⁻²)	30(28, 32)	29(27, 31)	30(27, 33)	0.37
Waist circumference (cm)	103(97, 108)	97(91, 104) [†]	101(97, 108) [‡]	0.03
Systolic BP (mmHg)	128(123, 134)	125(120, 130)	129(120,136)	0.23
Diastolic BP (mmHg)	79(74, 85)	76(74, 81)	78(71,85)	0.59
Fitness (L.min ⁻¹)	2.23 (1.61, 2.85)	2.73 (1.9,3.55) [†]	2.28 (1.63,2.93) [‡]	<0.01
Liver Enzymes				
ALT (u.l ⁻¹)	57(33, 81)	37(25, 48) [†]	67(40, 94) [‡]	0.05
AST (u.l ⁻¹)	39(26, 51)	28(24, 31) [†]	41(31, 51) [‡]	0.04
GGT (u.l ⁻¹)	85(18, 152)	60(18, 103)	68(38, 99)	0.26
Glucose and Lipid Profile				
Glucose (mmol.l ⁻¹)	5.0(4.6,5.4)	4.9(4.5, 5.3)	5.2(4.7, 5.6)	0.40
Cholesterol (mmol.l ⁻¹)	5.4(4.6, 6.1)	5.3(4.6, 5.9)	5.7(5.0, 6.5)	0.10
Triglyceride (mmol.l ⁻¹)	2.0(1.6,2.4)	1.9(1.6,2.2)	1.9(1.4, 2.4)	0.85
HDL (mmol.l ⁻¹)	1.4(1.2, 1.5)	1.4(1.3, 1.5)	1.5(1.3, 1.7)	0.16
LDL (mmol.l ⁻¹)	3.1(2.6, 3.6)	3.0(2.4, 3.6)	3.3(2.6, 4.0)	0.12
Chol:HDL ratio	3.8(3.3, 4.4)	3.8(3.1, 4.5)	3.9(3.2, 4.6)	0.89
Adipose tissue deposition				
VAT (l)	5.5(3.9, 7.1)	5.5(4.1, 6.8)	5.0(3.9, 6.0)	0.20
SAT (l)	8.2(6.0, 10.3)	7.7(5.6, 9.8)	7.9(5.0, 10.8)	0.27
Total abdominal AT (l)	13.7(11.3, 16.0)	13.1(11.2, 15.1)	12.8(9.1, 15.5)	0.23
Brachial Artery Function				
GTN-Mediated Dilation (%)	13.5(9.1, 17.8)	14.6(10.1, 19.0)	14.1(10.5, 18.7)	0.74

213

214 Data are presented as mean (95% CI). [†] Significantly different from baseline ($P<0.05$).

215 [‡] Significantly different from immediately following 16 weeks of supervised exercise training
 216 ($P<0.05$).

217 **BMI** Body mass index, **BP** blood pressure, **ALT** Alanine aminotransferase, **AST** Aspartate
 218 aminotransferase, **GGT** Gamma-glutamyltransferase, **HDL** High density lipoprotein, **LDL**
 219 Low density lipoprotein, **VAT** Visceral adipose tissue **SAT** Subcutaneous adipose tissue **AT**
 220 Adipose tissue **GTN** Glyceryl trinitrate

221 **References**

- 222 1. Adams LA, Lymp Jf Fau - St Sauver J, St Sauver J Fau - Sanderson SO, Sanderson
223 So Fau - Lindor KD, Lindor Kd Fau - Feldstein A, Feldstein A Fau - Angulo P *et al.*
224 The natural history of nonalcoholic fatty liver disease: a population-based cohort
225 study. *Gastroenterology* 2005; **129(1)**: 113-21.
- 226
- 227 2. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with
228 nonalcoholic fatty liver disease. *N Engl J Med* 2010; **363(14)**: 1341-50.
- 229
- 230 3. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. *Gut* 2007;
231 **56(12)**: 1760-1769.
- 232
- 233 4. Pugh CJ, Spring VS, Kemp GJ, Richardson P, Shojaee-Moradie F, Umpleby AM *et*
234 *al.* Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver
235 disease. *Am J Physiol Heart Circ Physiol* 2014; **307(9)**: H1298-306.
- 236
- 237 5. Cuthbertson DJ, Shojaee-Moradie F, Sprung VS, Jones H, Pugh CJ, Richardson P *et*
238 *al.* Dissociation between exercise-induced reduction in liver fat and changes in
239 hepatic and peripheral glucose homeostasis in obese patients with Non-Alcoholic
240 Fatty Liver Disease. *Clin Sci (Lond)* 2015.
- 241
- 242 6. Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP *et al.*
243 Modified high-intensity interval training reduces liver fat and improves cardiac
244 function in non-alcoholic fatty liver disease: A randomised controlled trial. *Clin Sci*
245 *(Lond)* 2015.
- 246
- 247 7. Sprung VS, Cuthbertson DJ, Pugh CJ, Aziz N, Kemp GJ, Daousi C *et al.* Exercise
248 training in polycystic ovarian syndrome enhances flow-mediated dilation in the
249 absence of changes in fatness. *Med Sci Sports Exerc* 2013; **45(12)**: 2234-42.

250

- 251 8. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD *et al.* Hepatic
252 triglyceride content and its relation to body adiposity: a magnetic resonance imaging
253 and proton magnetic resonance spectroscopy study. *Gut* 2005; **54**(1): 122-7.
- 254
- 255 9. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR *et al.*
256 Improved analysis of brachial artery ultrasound using a novel edge-detection software
257 system. *J Appl Physiol* 2001; **91**(2): 929-37.
- 258
- 259 10. Lesser IA, Dick T, Gasevic D, Mackey DC, Leipsic JA, Lear SA. The association
260 between physical activity and liver fat after five years of follow-up in a primary
261 prevention multi-ethnic cohort. *Prev Med* 2014; **67**: 199-203.
- 262
- 263 11. Keating SE, Hackett DA, Parker HM, O'Connor HT, Gerofi JA, Sainsbury A *et al.*
264 Effect of aerobic exercise training dose on liver fat and visceral adiposity. *J Hepatol*
265 2015; **63**(1): 174-82.
- 266
- 267 12. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by
268 flow-mediated vasodilatation of brachial artery: a meta-analysis. *The international*
269 *journal of cardiovascular imaging* 2010; **26**(6): 631-40.
- 270
- 271 13. Haufe S, Haas V, Utz W, Birkenfeld AL, Jeran S, Böhnke J *et al.* Long-lasting
272 improvements in liver fat and metabolism despite body weight regain after dietary
273 weight loss. *Diabetes Care* 2013; **36**(11): 3786-92.
- 274
- 275 14. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality
276 in non-alcoholic fatty liver disease. *J Hepatol* 2008; **49**(4): 608-12.
- 277
- 278 15. Haus JM, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR *et al.* Improved
279 hepatic lipid composition following short-term exercise in nonalcoholic fatty liver
280 disease. *J Clin Endocrinol Metab* 2013; **98**(7): E1181-8.

